No headlines found.
Business Wire 6-Aug 4:00 PM
Enanta's HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Nave HCV Patients with Compensated Cirrhosis
Business Wire 2-Aug 8:51 AM
Business Wire 15-Jul 7:30 AM
Business Wire 8-Jul 7:30 AM
Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)
Business Wire 14-Jun 6:00 AM
Business Wire 10-Jun 4:00 PM
Stock Price | Full Chart
|Correlated Symbol||Name||Sector||R-Squared||Beta||Current Price||% Chg|
This correlation is calculated using one year's worth of weekly returns.
An R-Squared of 1.00 is the maximum value. Beta is only significant when the R-Squared is a high value.